Fadi Fakhouri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/186839/publications.pdf

Version: 2024-02-01

63 papers	6,402 citations	117625 34 h-index	128289 60 g-index
64 all docs	64 docs citations	64 times ranked	4438 citing authors

#	Article	IF	Citations
1	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. American Journal of Kidney Diseases, 2022, 79, 56-68.e1.	1.9	11
2	Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients. Kidney and Dialysis, 2022, 2, 6-15.	1.0	0
3	What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study. BMC Nephrology, 2022, 23, 39.	1.8	8
4	The Rational Use of Complement Inhibitors in Kidney Diseases. Kidney International Reports, 2022, 7, 1165-1178.	0.8	16
5	Malignant hypertension and thrombotic microangiopathy: complement as a usual suspect. Nephrology Dialysis Transplantation, 2021, 36, 1157-1159.	0.7	3
6	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood, 2021, 137, 2438-2449.	1.4	87
7	Atypical HUS relapse triggered by COVID-19. Kidney International, 2021, 99, 267-268.	5.2	46
8	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
9	Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. Journal of Nephrology, 2021, 34, 1581-1590.	2.0	23
10	Eosinophilia Due to Central Venous Catheter in Hemodialysis Patients. Kidney International Reports, 2021, 6, 1189-1191.	0.8	1
11	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nature Reviews Nephrology, 2021, 17, 543-553.	9.6	64
12	High levels of interleukine-6 in ascites prevent ascites reinfusion during hemodialysis. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101734.	1.5	0
13	Letter regarding â€œMinimal change disease relapse following SARS-CoV-2 mRNA vaccineâ€• Kidney International, 2021, 100, 458-459.	5.2	24
14	Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1355-1364.	4.5	6
15	COVID-19 as a potential trigger of complement-mediated atypical HUS.. Blood, 2021, 138, 1777-1782.	1.4	18
16	C3 glomerulonephritis in a patient treated with antiâ€“PD-1 antibody. European Journal of Cancer, 2020, 125, 46-48.	2.8	6
17	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
18	Antenatal corticosteroid therapy and COVIDâ€19: Pathophysiological considerations. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 952-952.	2.8	11

#	Article	IF	Citations
19	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney International, 2020, 98, 1135-1148.	5.2	28
20	Collapsing glomerulopathy in a COVID-19 patient. Kidney International, 2020, 98, 228-231.	5.2	240
21	The authors reply. Kidney International, 2020, 98, 232.	5.2	3
22	The authors reply. Kidney International, 2019, 96, 517-518.	5.2	0
23	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
24	Etiology and Outcomes of Thrombotic Microangiopathies. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 557-566.	4.5	89
25	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica, 2019, 104, 2501-2511.	3.5	40
26	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	6.1	81
27	Shiga toxinâ€“producing Escherichia coliâ€“associated hemolytic uremic syndrome in solid organ transplant recipients. Kidney International, 2019, 96, 1423-1424.	5.2	5
28	Monitoring Complement Activation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1682-1683.	4.5	3
29	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2019, 4, 434-446.	0.8	59
30	Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 641-650.	5.6	23
31	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 84-92.	1.9	94
32	Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. Seminars in Arthritis and Rheumatism, 2018, 48, 70-76.	3.4	27
33	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andÂoutcome. Kidney International, 2018, 94, 408-418.	5.2	117
34	Haemolytic uraemic syndrome. Lancet, The, 2017, 390, 681-696.	13.7	397
35	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
36	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1237-1247.	4.5	146

#	Article	IF	Citations
37	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	5.2	93
38	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 50-59.	4.5	148
39	Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. Antibodies, 2017, 6, 19.	2.5	10
40	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases, 2016, 68, 84-93.	1.9	230
41	Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatric Nephrology, 2016, 31, 41-51.	1.7	13
42	Loss of DGKÎµ induces endothelial cell activation and death independently of complement activation. Blood, 2015, 125, 1038-1046.	1.4	69
43	Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy. American Journal of Kidney Diseases, 2015, 65, 484-489.	1.9	87
44	Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. Nephrology Dialysis Transplantation, 2014, 29, 1225-1231.	0.7	14
45	Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. American Journal of Kidney Diseases, 2014, 63, 40-48.	1.9	74
46	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genetics, 2013, 45, 531-536.	21.4	419
47	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 554-562.	4.5	567
48	C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089.	5.2	505
49	Eculizumab for atypical haemolytic uraemic syndrome: what next?. Nature Reviews Nephrology, 2013, 9, 495-496.	9.6	10
50	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology: JASN, 2010, 21, 859-867.	6.1	383
51	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney International, 2010, 78, 279-286.	5.2	94
52	C3 glomerulopathy: a new classification. Nature Reviews Nephrology, 2010, 6, 494-499.	9.6	314
53	Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases. CKJ: Clinical Kidney Journal, 2009, 2, 143-146.	2.9	3
54	Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood, 2008, 112, 4542-4545.	1.4	112

#	Article	IF	Citations
55	Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. Nature Clinical Practice Nephrology, 2007, 3, 679-687.	2.0	53
56	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. Journal of Medical Genetics, 2006, 44, 193-199.	3.2	259
57	ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrology Dialysis Transplantation, 2005, 20, 1392-1399.	0.7	150
58	The man with â€œmilk-shakeâ€•urine. Lancet, The, 2004, 364, 1638.	13.7	2
59	Steroid-sensitive nephrotic syndrome: From childhood to adulthood. American Journal of Kidney Diseases, 2003, 41, 550-557.	1.9	164
60	The expanding spectrum of renal diseases associated with antiphospholipid syndrome. American Journal of Kidney Diseases, 2003, 41, 1205-1211.	1.9	93
61	Crystals from fat. Nephrology Dialysis Transplantation, 2002, 17, 1348-1350.	0.7	15
62	Mesangial IgG Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 379-387.	6.1	15
63	Liver Involvement in Autosomal-Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2000, 11, 1767-1775.	6.1	127